Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study).
Frailty
Geriatric 8
Prostate cancer
Quality of life
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
05
08
2020
accepted:
28
09
2020
pubmed:
21
10
2020
medline:
16
2
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown. We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8 ≤ 14) on worse QOL. The median age of patients was 70 years. There were 369 (surgery: 196, radiotherapy: 156, androgen deprivation therapy alone: 17) patients in the M0 and 40 patients in the mCSPC groups. There was a significant difference between the M0 and mCSPC groups in the G8 score (14.5 vs. 12.5), functioning QOL (94 vs. 87), global QOL (75 vs. 58), and 100-symptom QOL (94 vs. 85) scores. G8 scores were significantly associated with functioning, global, and 100-symptom QOL scores in both M0 and mCSPC groups. The multivariable logistic regression analyses showed that frailty (G8 ≤ 14) was significantly associated with worse global QOL, functioning QOL, and 100-symptom QOL scores. The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.
Sections du résumé
BACKGROUND
BACKGROUND
The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown.
METHODS
METHODS
We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8 ≤ 14) on worse QOL.
RESULTS
RESULTS
The median age of patients was 70 years. There were 369 (surgery: 196, radiotherapy: 156, androgen deprivation therapy alone: 17) patients in the M0 and 40 patients in the mCSPC groups. There was a significant difference between the M0 and mCSPC groups in the G8 score (14.5 vs. 12.5), functioning QOL (94 vs. 87), global QOL (75 vs. 58), and 100-symptom QOL (94 vs. 85) scores. G8 scores were significantly associated with functioning, global, and 100-symptom QOL scores in both M0 and mCSPC groups. The multivariable logistic regression analyses showed that frailty (G8 ≤ 14) was significantly associated with worse global QOL, functioning QOL, and 100-symptom QOL scores.
CONCLUSION
CONCLUSIONS
The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.
Identifiants
pubmed: 33079283
doi: 10.1007/s10147-020-01798-4
pii: 10.1007/s10147-020-01798-4
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-206Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19H05556
Organisme : Japan Society for the Promotion of Science
ID : 18K09157
Organisme : Japan Society for the Promotion of Science
ID : 20K09517
Organisme : Japan Society for the Promotion of Science
ID : 20K18082
Organisme : Japan Society for the Promotion of Science
ID : 20K18130
Organisme : Japan Society for the Promotion of Science
ID : 20K18107
Références
Culp MB, Soerjomataram I, Efstathiou JA et al (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38–52. https://doi.org/10.1016/j.eururo.2019.08.005
doi: 10.1016/j.eururo.2019.08.005
pubmed: 31493960
Kimura T, Egawa S (2018) Epidemiology of prostate cancer in Asian countries. Int J Urol 25(6):524–531. https://doi.org/10.1111/iju.13593
doi: 10.1111/iju.13593
pubmed: 29740894
Ito K, Oki R, Sekine Y et al (2019) Screening for prostate cancer: history, evidence, controversies and future perspectives toward individualized screening. Int J Urol 26(10):956–970. https://doi.org/10.1111/iju.14039
doi: 10.1111/iju.14039
pubmed: 31183923
Isharwal S, Johanning JM, Dwyer JG et al (2017) Preoperative frailty predicts postoperative complications and mortality in urology patients. World J Urol 35(1):21–26. https://doi.org/10.1007/s00345-016-1845-z
doi: 10.1007/s00345-016-1845-z
pubmed: 27172940
Suskind AM, Walter LC, Jin C et al (2016) Impact of frailty on complications in patients undergoing common urological procedures: a study from the American college of surgeons national surgical quality improvement database. BJU Int 117(5):836–842. https://doi.org/10.1111/bju.13399
doi: 10.1111/bju.13399
pubmed: 26691588
pmcid: 4833543
Soma O, Hatakeyama S, Okamoto T et al (2019) Multicenter prospective study validating the efficacy of a quantitative assessment tool for frailty in patients with urological cancers. Med Oncol 36(10):88. https://doi.org/10.1007/s12032-019-1313-x
doi: 10.1007/s12032-019-1313-x
pubmed: 31520152
Xue QL (2011) The frailty syndrome: definition and natural history. Clin Geriatr Med 27(1):1–15. https://doi.org/10.1016/j.cger.2010.08.009
doi: 10.1016/j.cger.2010.08.009
pubmed: 21093718
pmcid: 3028599
Soma O, Hatakeyama S, Imai A et al (2020) Relationship between frailty and lower urinary tract symptoms among community-dwelling adults. Low Urin Tract Symptoms 12(2):128–136. https://doi.org/10.1111/luts.12292
doi: 10.1111/luts.12292
pubmed: 31642610
Kodama H, Hatakeyama S, Momota M et al (2020) Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study). Urol Oncol. https://doi.org/10.1016/j.urolonc.2020.06.019
doi: 10.1016/j.urolonc.2020.06.019
pubmed: 32684512
Momota M, Hatakeyama S, Soma O et al (2020a) Frailty is a predictor of moderate to severe pain after robot-assisted laparoscopic prostatectomy: a case-control study (FRAP study). BJUI Compass 1(3):100–107. https://doi.org/10.1002/bco2.17
doi: 10.1002/bco2.17
Levy I, Finkelstein M, Bilal KH et al (2017) Modified frailty index associated with Clavien-Dindo IV complications in robot-assisted radical prostatectomies: a retrospective study. Urol Oncol 35(6):425–431. https://doi.org/10.1016/j.urolonc.2017.01.005
doi: 10.1016/j.urolonc.2017.01.005
pubmed: 28190748
Taylor BL, Xia L, Guzzo TJ et al (2019) Frailty and greater health care resource utilization following major urologic oncology surgery. Eur Urol Oncol 2(1):21–27. https://doi.org/10.1016/j.euo.2018.06.005
doi: 10.1016/j.euo.2018.06.005
pubmed: 30929842
Molina-Garrido MJ, Guillen-Ponce C (2017) Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Rev Aging Male 20(2):102–109. https://doi.org/10.1080/13685538.2016.1277516
doi: 10.1080/13685538.2016.1277516
Droz JP, Albrand G, Gillessen S et al (2017) Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol 72(4):521–531. https://doi.org/10.1016/j.eururo.2016.12.025
doi: 10.1016/j.eururo.2016.12.025
pubmed: 28089304
Momota M, Hatakeyama S, Soma O et al (2020b) Geriatric 8 screening of frailty in patients with prostate cancer. Int J Urol 27(8):642–648. https://doi.org/10.1111/iju.14256
doi: 10.1111/iju.14256
pubmed: 32500621
Decoster L, Van Puyvelde K, Mohile S et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 26(2):288–300. https://doi.org/10.1093/annonc/mdu210
doi: 10.1093/annonc/mdu210
pubmed: 24936581
Fukushi K, Narita T, Hatakeyama S et al (2017a) Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma. Int J Urol 24(5):361–366. https://doi.org/10.1111/iju.13318
doi: 10.1111/iju.13318
pubmed: 28258623
Husson O, de Rooij BH, Kieffer J et al (2020) The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “real-world”: results from the population-based PROFILES registry. Oncologist 25(4):e722–e732. https://doi.org/10.1634/theoncologist.2019-0348
doi: 10.1634/theoncologist.2019-0348
pubmed: 32297435
Shirk JD, Saigal CS (2017) From QOL to QALYs: Comparing nononcologic outcomes in prostate cancer survivors across treatments. Urol Oncol 35(2):69–75. https://doi.org/10.1016/j.urolonc.2016.07.019
doi: 10.1016/j.urolonc.2016.07.019
pubmed: 27575917
Van Hemelrijck M, Sparano F, Moris L et al (2020) Harnessing the patient voice in prostate cancer research: systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making. Cancer Med 9(12):4039–4058. https://doi.org/10.1002/cam4.3018
doi: 10.1002/cam4.3018
pubmed: 32333639
pmcid: 7300413
Chen MN, Ho KY, Hung YN et al (2019) Pre-treatment quality of life as a predictor of distant metastasis-free survival and overall survival in patients with head and neck cancer who underwent free flap reconstruction. Eur J Oncol Nurs 41:1–6. https://doi.org/10.1016/j.ejon.2019.05.003
doi: 10.1016/j.ejon.2019.05.003
pubmed: 31358241
Frantellizzi V, De Feo MS, Di Rocco A et al (2020) Baseline quality of life predicts overall survival in patients with mCRPC treated with (223)Ra-dichloride. Hell J Nucl Med 23(1):12–20. https://doi.org/10.1967/s002449912001
doi: 10.1967/s002449912001
pubmed: 32222727
Suppanuntaroek S, Hatakeyama S, Fujita N et al (2020) Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma. Int J Clin Oncol 25(2):362–369. https://doi.org/10.1007/s10147-019-01563-2
doi: 10.1007/s10147-019-01563-2
pubmed: 31655941
Quinten C, Kenis C, Hamaker M et al (2020) The added value of geriatric assessment in evaluating a patient’s health-related quality-of-life: a study in ≥70-year-old early-stage invasive breast cancer patients. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.13278
doi: 10.1111/ecc.13278
Biesma B, Wymenga ANM, Vincent A et al (2011) Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol 22(7):1520–1527. https://doi.org/10.1093/annonc/mdq637
doi: 10.1093/annonc/mdq637
pubmed: 21252061
Knight J, Ayyash K, Colling K et al (2020) A cohort study investigating the relationship between patient reported outcome measures and pre-operative frailty in patients with operable, non-palliative colorectal cancer. BMC Geriatr 20(1):311. https://doi.org/10.1186/s12877-020-01715-4
doi: 10.1186/s12877-020-01715-4
pubmed: 32854632
pmcid: 7453711
Kobayashi K, Takeda F, Teramukai S et al (1998) A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34(6):810–815. https://doi.org/10.1016/s0959-8049(97)00395-x
doi: 10.1016/s0959-8049(97)00395-x
pubmed: 9797690
Fukushi K, Narita T, Hatakeyama S et al (2017b) Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol 22(2):366–372. https://doi.org/10.1007/s10147-016-1071-0
doi: 10.1007/s10147-016-1071-0
pubmed: 27933402
Amiya Y, Yamada Y, Sugiura M et al (2017) Outcomes of patients older than 75 years with non-metastatic prostate cancer. Asian J Urol 4(2):102–106. https://doi.org/10.1016/j.ajur.2016.12.001
doi: 10.1016/j.ajur.2016.12.001
pubmed: 29264213
pmcid: 5717973
Nguyen-Nielsen M, Moller H, Tjonneland A et al (2020) Patient-reported outcome measures after treatment for prostate cancer: results from the Danish prostate cancer registry (DAPROCAdata). Cancer Epidemiol 64:101623. https://doi.org/10.1016/j.canep.2019.101623
doi: 10.1016/j.canep.2019.101623
pubmed: 31760356
Cheung AS, de Rooy C, Hoermann R et al (2017) Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clin Endocrinol (Oxf) 86(3):388–394. https://doi.org/10.1111/cen.13249
doi: 10.1111/cen.13249
Joly F, Oudard S, Fizazi K et al (2020) Quality of life and pain during treatment of metastatic castration-resistant prostate cancer with cabazitaxel in routine clinical practice. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2020.02.003
doi: 10.1016/j.clgc.2020.02.003
pubmed: 32229267